Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

65

P751 A Model to Predict Idiopathic Pulmonary Fibrosis Outcomes Using Artificial Intelligence/ K. Ussavarungsi, Cleveland, OH

P739 Sex Differences in Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease by Pattern/ Y. Sugawara, Aurora, CO P740 Association Between Smoking and Clinical Outcome in Patients With Idiopathic Pulmonary Fibrosis: A Nationwide Population-based Study/ H.-Y. Yoon, Seoul, Korea, Republic of P741 Progression in Fibrotic Interstitial Lung Diseases - Prevalence and Indicators in the Initial Evaluation in a Brazilian Multicentric Cohort/ C.L. Resende, Sao Paulo, Brazil P742 Current Definitions of Progressive Pulmonary Fibrosis Might Be Inaccurate: Data From a Cohort of Patients With Rheumatoid Arthritis Associated Interstitial Lung Disease/ M. Vermant, Leuven, Belgium P743 Clustering Analysis of HRCT Parameters Measured Using a Texture-based Automated System: Relationship With Clinical Outcomes of IPF Patients/ J.S. Park, Bucheon, Korea, Republic of P744 Biomarkers Extracted by Fully Automated Body Composition Analysis From Chest CT Correlate With Survival in Idiopathic Pulmonary Fibrosis (IPF)/ F. Bonella, Essen, Germany P745 Circulating Urokinase-Type Plasminogen Activator Receptor Protein Highly Correlates With the Severity of Idiopathic Pulmonary Fibrosis (IPF): Data From the IPF-PRO Registry/ J.L. Todd, Durham, NC P746 Bronchoalveolar Lavage (BAL) Fluid Cytokine and Chemokine Analysis in Interstitial Lung Disease (ILD)- Can It Predict Progressive Fibrotic Phenotype?/ N. Iannazzo, Indianapolis, IN P747 Neutrophil Extracellular Trap Associated Proteins in Bronchoalveolar Lavage Fluid Are Associated With Worse Baseline Lung Function and Worse Survival in Patients With Idiopathic Pulmonary Fibrosis/ S. Matson, Kansas City, KS P748 Clinical Features and Outcomes of Patients With Myositis Associated-Interstitial Lung Disease/ T. Karampitsakos, Patras, Greece P749 Identification of Molecular Profiles Predictive of Outcome by RNA-Sequencing of Formalin-Fixed, Paraffin-Embedded (FFPE) Lung Tissue From Patients With Idiopathic Pulmonary Fibrosis/ T. Karampitsakos, Tampa, FL P750 Quantitative High-Resolution Computed Tomography Predicts Progressive Pulmonary Fibrosis/ M. Koslow, Denver, CO

CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION

A39

MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area G, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion

12:15-1:15 authors will be present for discussionwith assigned facilitators.

P753 Burden and Trends in Secondary Pulmonary

Hypertension and Associated Inpatient Outcomes in Elderly Patients Hospitalized With Autoimmune Disorders: A Nationwide Analysis, 2016-2019/ J. Jasti, Sioux Falls, SD

P754 Pulmonary Hypertension Was Associated With Increased Risk of Mortality in Patients With Combined Pulmonary Fibrosis and Emphysema/ A.S. Sadigov, Baku, Azerbaijan P755 Survival After Secondary Spontaneous Pneumothorax in Interstitial Lung Disease/ A. Coolidge, Boston, MA P756 The Prognostic Value of Gastroesophageal Reflux Disorder in Interstitial Lung Disease Related Hospitalizations: Insight From National Inpatient Sample/ S. Alqalyoobi, Greenville, NC P757 Esophageal-gastric Sphincter Weakness in Chronic Lung Disease/ J.K. Joshua, San Diego, CA P758 Prevalence of Interstitial Lung Abnormalities in Patients With Achalasia Requiring Peroral Endoscopic Myotomy Procedure/ D.R. Kramer, Philadelphia, PA P759 Health-related Quality of Life in Patients With Rheumatoid Arthritis (RA) Vs RA-associated Interstitial Lung Disease/ Y. Sugawara, Aurora, CO P760 Dyspnea During Sexual Activity in Patients With Fibrotic Interstitial Lung Disease/ N. Avitzur, Calgary, Canada P761 Laryngology Evaluation and Management of Chronic Cough in Interstitial Lung Disease Patients/ S.K. Mathai, Dallas, TX P762 Pregabalin for Interstitial Lung Disease-related Cough: A Single-center Experience/ M.D. Saint-Pierre, Ottawa, Canada

ATS 2023 • Washington, DC